Efficacy of BRAF Inhibitor FORE8394 in BRAF V600+ Patients

Press Release Sep 12 2022 Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022 Read more

Press Release Apr 18 2022 Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer Read more

Press Release Sep 20 2021 Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments Read more